Avidity Biosciences, Inc., a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), entered a global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.    AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide thera...